Understanding of BRCA VUS genetic results by breast cancer specialists
Tóm tắt
Mainstreaming genetic medicine, increased media coverage and clinical trials for BRCA mutation carriers are leading oncologists into more patient discussions about BRCA genetic testing. BRCA variants of uncertain significance (VUS) occur in 10–20 % of tests. VUS detection introduces additional uncertainty for patient and potentially clinician. We aimed to explore the ability of breast cancer specialists (BCS) in the UK to correctly respond to a VUS report. A survey sent to 800 UK BCS collected demographics data, VUS general knowledge and interpretation and communication based on two genetics reports. A separate survey of UK clinical geneticists collected demographics data, laboratory reporting practice and methods used to clarify VUS pathogenicity including classification systems. Of the 155 BCS (22.5 %) who completed the survey, 12 % reported no genetics training. Ninety five percent referred patients for BRCA genetic tests, 71 % felt unsure about the clinical implications of the test reports presented here. A VUS report from a patient with a positive family history was interpreted and theoretically communicated correctly by 94 % but when presented with a different VUS report with no management guidance and negative family history, 39 % did not know how to communicate this result to the patient. Geneticists reported multiple VUS classification systems; the most commonly used was word-based in 32 %. A consistent and standardised format to report particularly VUS results across all diagnostic laboratories plus additional training of UK BCS will be necessary for effective mainstreaming of BRCA testing to the oncology clinic.
Tài liệu tham khảo
Easton DF, Ford D, Bishop DT, Breast Cancer linkage Consortium. Breast and Ovarian Cancer Incidence in BRCA1-Mutation Carriers. Am J Hum Genet. 1995;S6:265–71.
Miki Y, Swenson J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71.
Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C. BRCA1 mutations in primary breast and ovarian cancers. Science. 1994;266:120–2.
Evans DG, Barwell J, Eccles DM, Collins A, Izatt L, Jacobs C, et al. The Angelina Jolie effect: How high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res. 2014;16:442.
Raphael J Verma S, Hewitt P, and Eisen A: The impact of Angelina Jolie's (AJ) story on genetic referral and testing at an academic cancer centre. J Clin Oncol 2014, 32 suppl 26; abstr 44
Familial breast cancer NICE guidelines CG164 [http://www.nice.org.uk/guidance/cg164]. Accessed June 2015.
Burton H: Genetics and mainstream medicine. PHG Foundation. 2011: ISBN 978-1-907198-07-6. http://www.phgfoundation.org/file/7962/.
Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29:1282–91. doi:10.1002/humu.20880.
Spurdle AB, Whiley PJ, Thompson B, Feng B, Healey S, Brown MA, et al. BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. J Med Genet. 2012;49(8):525–32.
Lindor NM, Goldgar DE, Tavtigian SV, Plon SE, Couch FJ. BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management. Oncologist. 2013;18:518–24.
Ready K, Gutierrez-Barrera AM. Amos et al: Cancer risk management decisions in women with BRCA1 or 2 variants of uncertain significance. Breast J. 2011;17:210–2.
Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, et al. A Systematic Genetic Assessment of 1,433 Sequence Variants of Unknown Clinical Significance in the BRCA1 and BRCA2 Breast Cancer–Predisposition Genes. Am J Hum Genet. 2007;81:873–83.
Practice Guidelines for the Evaluation of Pathogenicity and the Reporting of Sequence Variants in Clinical Molecular Genetics. [http://www.acgs.uk.com/media/774853/evaluation_and_reporting_of_sequence_variants_bpgs_june_2013_-_finalpdf.pdf]. Accessed June 2015.
Culver JO, Brinkerhoff CD, Clague J, Yang K, Singh KE, Sand SR, et al. Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress. Clin Genet. 2013;84:464–72. doi:10.1111/cge.12097.
Escher M, Sappino AP. Primary Care physicians’ knowledge and attitudes towards genetic testing for breast-ovarian cancer predisposition. Ann Oncol. 2000;11:1131–5.
Ardern-Jones A, Kenen R, Eeles R. Too much, too soon? Patients and health professionals’ views concerning the impact of genetic testing at the time of breast cancer diagnosis in women aged under the age of 40. Eur J Cancer Care. 2005;14:272–81.
Van Riel E, Warlam-Rodenhuis CC, Verhoef S, Rutgers EJTH, Ausems MGEM. BRCA testing of breast cancer patients: medical specialists’ referral patterns, knowledge and attitudes to genetic testing. Eur J Cancer. 2010;19:369–76.
Keating N, Stoeckert KA, Regan MM, DiGianni L, Garber JE. Physicians‘Experiences with BRCA 1/2 testing in Community Settings. JCO. 2008;26:5789–96.
Doksum T, Berhardt BA, Holtzman NA. Does knowledge about the genetics of breast cancer differ between nongenetists physicians who do or do not discuss or order BRCA testing? Genet Med. 2003;5:99–105.
Petrucelli N, Lazebnik N, Huelsman KM, Lazebnik RS. Clinical Interpretation and Recommendations for Patients with a Variant of Uncertain Significance in BRCA1 or BRCA2: A survey of Genetic Counselling Practice. Genet Test. 2002;6:107–13.
Richter S, Haroun I, Graham TC, Eisen A, Kiss A, Warner E. Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling. Ann Oncol. 2013;24 Suppl 8:viii69–74.
Spurdle AB, Healey S, Devereau A, Hogervorst FBL, Monteiro ANA, Nathanson KL, et al. ENIGMA—Evidence-based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat. 2012;33:2–7.
Plon SE, Cooper HP, Parks B, Dhar S, Kelly PA, Weinberg AD, et al. Genetic Testing and Cancer Risk Management Recommendations by Physicians for At-Risk Relatives. Genet Med. 2011;13(2):148–54.
Vink GR, Asperen CJ, Devilee P, Breuning MH, Bakker E. Unclassified variants in disease-causing genes: nonuniformity of genetic testing and counselling, a proposal for guidelines. Eur J Hum Genet. 2005;13:525–7.
Lindor NM, Guidugli L, Wang X, Vallee MP, Monteiro ANA, Tavtigian S, et al. A Review of a Multifactorial Probability-Based Model for Classification of BRCA1 and BRCA2 Variants of Uncertain Significance (VUS). Hum Mutat. 2012;33(1):8–21.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–23.
Radice P, De Summa S, Caleca L, Tommasi S. Unclassified variants in BRCA genes: guidleines for interpretation. Ann Oncol. 2011;22(supp1):i18–23.
Brierley KL, Campfield D, Ducaine W, Dohany L, Donenberg T, Shannon K, et al. Errors in delivery of cancer genetics services: implications for practice. Conn Med. 2010;74(7):413–23.
Brierley KL, Blouch E, Cogswell W, Homer JP, Pencarinha D, Stanislaw CL, et al. Adverse events in cancer genetic testing: medical, ethical, legal, and financial implications. Cancer J. 2012;18(4):303–9.
Murray ML, Cerrato F, Bennett RL, Jarvik GP. Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions. Genet Med. 2011;13(12):998–1005.
Vos J, Otten W, van Asperen C, Jansen A, Menko F, Tibben A. The counsellees’ view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life. Psycho-Oncology. 2008;17:822–30. doi:10.1002/pon.1311.
GTEOC - Genetic Testing in Epithelial Ovarian Cancer [http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=13223]. Accessed June 2015.
NCRN - 2802 OlympiAD Olaparib vs Physician's Choice in BRCA mutated metastatic breast cancer [http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=16109]. Accesed June 2015.